Allogene Therapeutics, Inc.

Our Board is committed to continuous improvement and conducts a robust annual self-assessment process designed to enhance Board effectiveness and governance practices by evaluating overall Board performance as well as individual director performance. The Nominating and Corporate Governance Committee oversees this evaluation process, including reviewing and approving the self-assessment questionnaire and the methodology used, consistent with our Corporate Governance Guidelines.

In 2026, the Board evaluation was facilitated through an extensive, structured questionnaire addressing key areas such as Board composition, information flow, operational efficiency, Board engagement and interaction, accountability, individual director contributions, and performance related to strategic decision-making.

All continuing directors participated fully in the evaluation, providing comprehensive, anonymous and candid feedback. An independent third-party advisor is used to collect, analyze, and summarize the directors' responses to preserve anonymity and objectivity, further enhancing the integrity of the assessment. The advisor will present detailed findings to each respective committee, and collectively to the full Board, fostering in-depth discussions focused on identified strengths and specific opportunities for improvement.

Key topics covered in the evaluation include:

•The effectiveness of our current Board leadership structure and independence.

•Quality, timeliness, and relevance of information provided to directors.

•Efficiency and effectiveness of Board and committee meetings.

•Board’s strategic oversight and response to evolving business challenges.

•Assessment of risk oversight processes and management accountability.

•Individual and collective director contributions and areas for skill enhancement.

Following the evaluation, the Board and each committee identify actionable steps to address feedback, improve governance processes, and enhance Board and committee performance. This iterative process underscores the Board’s proactive approach to governance, promoting transparency, accountability, and long-term value creation for our stockholders.